Adding diclofenac to single-agent immunotherapy for metastatic non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II study gives oral diclofenac potassium twice daily to patients already receiving a single‑agent PD‑1/PD‑L1 immunotherapy (pembrolizumab, atezolizumab, nivolumab, or cemiplimab) who have had at least 12 weeks of therapy and show radiographic signs of early progression. Patients continue their standard immunotherapy on 21‑ or 28‑day cycles while taking diclofenac until disease progression or unacceptable toxicity. The primary endpoint is clinical benefit rate, with secondary endpoints focused on safety, tolerability, and measures of efficacy. Exploratory analyses will profile circulating CD8 and CD4 T cells, B cells, PD‑L1 expression, serum lactic acid, and tumor microenvironment features to understand immune changes related to diclofenac exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Capable of signing informed consent
* Age ≥ 18 years at time of study entry
* Stage III or IV pathologically proven NSCLC with advanced or metastatic disease, currently on treatment with an Food and Drug Administration (FDA) approved single agent monoclonal antibody inhibiting the PD(L)-1 pathway (pembrolizumab, atezolizumab, nivolumab, or cemiplimab) for a minimum of 12 weeks

  * May include frontline single agent immune checkpoint inhibitors (ICI), maintenance single agent ICI after chemo-ICI, or subsequent line therapy
* Radiographic evidence of clinical progression as determined by the treating physician, not warranting immediate change of therapy. Progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria is not required. This can include mixed response, will need at least one growing lesion. Exposure to PD1 inhibitor for at least 12 weeks will minimize the risk of pseudo-progression
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Life expectancy of ≥ 26 weeks
* Absolute neutrophil count (ANC) ≥ 1,000 cell/mm\^3
* Platelets ≥ 100,000 cells/mm\^3
* Hemoglobin ≥ 8 gm/dL
* Creatinine clearance ≥ 45 ml/ml
* Bilirubin ≤ 1.5 x institutional upper limit of normal

  * Bilirubin must be ≤ 3 x institutional upper limit of normal in patients with documented Gilbert's syndrome
* Serum glutamic oxaloacetic transaminase (SGOT) / serum gluatmic pyruvic transaminase (SGPT) ≤ 2.5 x institutional upper limit of normal
* Ability to take oral medications
* Willingness and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Exclusion Criteria:

* Concurrent enrollment in another clinical study, unless it is non-therapeutic
* Prophylactic or therapeutic anticoagulation therapy including but not limited to: warfarin, heparin, low molecular weight heparin, or direct oral anticoagulants, including: dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa)
* Treatment within the previous 6 weeks or planned initiation of bevacizumab
* Abnormal markers of coagulation as measured by international normalized ratio (INR) \> 2
* Contraindication for NSAID therapy including: chronic aspirin therapy for coronary artery disease (CAD), cerebrovascular accident (CVA), or other indication, uncontrolled gastrointestinal ulcerative disease, known bleeding diathesis, known allergy or hypersensitivity to NSAIDS, advanced renal disease, uncontrolled hypertension, known seizure disorder or others
* Female of childbearing potential unwilling or unable to use 2 methods of contraception, detailed in protocol
* Uncontrolled intercurrent illness
* History of another primary malignancy with exceptions noted in protocol
* History of active primary immunodeficiency or active infection including tuberculosis, hepatitis B, hepatitis C
* Current or prior use of immunosuppressive medication within 14 days before the first dose of diclofenac. There are exceptions to this criterion
* Receipt of live attenuated vaccine within 30 days prior to the first dose of study medications
* Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements

Where it's running

• Emory University Hospital Midtown
  Atlanta, Georgia, United States Recruiting
• Emory University Hospital/Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Jennifer W Carlisle — Emory University Hospital/Winship Cancer Institute
• Study coordinator: Kajona McCall
• Email: kajohna.mccall@emory.edu
• Phone: 404-778-5087

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• SX-682 with Atezolizumab for advanced or metastatic NSCLC

  This phase 2 trial tests whether combining SX-682 with atezolizumab can help people with advanced, metastatic, or recurrent NSCLC who have progressed after prior treatments.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07322341

• GT103 plus pembrolizumab for advanced STK11‑mutant non‑small cell lung cancer

  This trial tests whether adding GT103 to pembrolizumab can help adults with advanced or metastatic STK11‑mutant non‑small cell lung cancer.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT07017829

• Combining carfilzomib and sotorasib for treating advanced lung cancer with KRAS G12C mutation

  This study is testing a new combination of two drugs, carfilzomib and sotorasib, to see if it can safely help people with advanced lung cancer that has a specific KRAS G12C mutation after they have tried other treatments.

  Recruiting at 2 sites Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06249282

• Combining sotorasib and trastuzumab deruxtecan for advanced KRAS G12C non-small cell lung cancer

  This trial tests whether giving sotorasib with trastuzumab deruxtecan is safe and can shrink tumors or slow progression in people with locally advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation and progressed after prior targeted therapy, immunotherapy, and chemotherapy.

  Recruiting at 9 sites Phase 1/2 National Cancer Institute (NCI) · Sacramento, California and 8 other locations · NCT07012031

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.